arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

OnKure Therapeutics, Inc.

OKUR

$4.13 ▼ -0.03 (-0.60%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

OnKure Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -88.5% ↘

FCF / Share $-3.84 ↗

Trailing P/E —

Price / Book 1.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-59.52M

↓ -13.0% —

FCF / Share Free cash flow per share

$-3.84

↑ +74.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	71.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-506.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-18.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	3.2% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	77.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-13.0% Weak ↑ Weak Improving Year-over-year change in net income	31.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-49.0% Weak ↑ Weak Improving Year-over-year change in net income	-30.6% Weak Weak Year-over-year change in net income	-104.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	74.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-612.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	-7.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	7.5% Fair Fair Year-over-year change in free cash flow	77.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	—	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-88.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-93.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	46.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-101.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-77.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-35.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-105.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-806%)	-50.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-438%)	-87.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-682%)	-52.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-446%)	-27.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-280%)	46.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+208%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-59.05M	$-110.76M	$-27.63M	$-19.93M	$-124.66M	$-53.61M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-4.40	$-15.28	$-2.52	$-2.12	$-2.19	$-9.60	—
Free Cash Flow per Share (USD)	$-3.84	$-14.84	$-2.08	$-1.95	$-2.10	$-9.15	—
Book Value per Share (USD)	$4.16	$30.12	$2.65	$4.05	$6.02	$-20.51	—
Tangible Book Value per Share (USD)	$4.16	$30.12	$2.65	$4.05	$6.02	$-20.51	—
Basic Weighted Avg Shares (shares)	13.52M	3.45M	30.68M	24.50M	18.14M	2.03M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$54.92M	$102.47M	$88.44M	$99.23M	$147.53M	$50.45M	—
Total Equity (USD)	$56.18M	$103.83M	$88.61M	$99.97M	$147.21M	$-42.12M	$-23.13M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$447.00K	$459.00K	$170.00K	$88.00K	$50.00K	$37.00K	—
Net Income, GAAP (USD)	$-59.52M	$-52.67M	$-77.39M	$-51.95M	$-39.77M	$-19.46M	—
Operating Cash Flow (USD)	$-51.83M	$-51.12M	$-63.68M	$-47.36M	$-37.98M	$-18.54M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

OnKure Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare OKUR with peers